CLOs on the Move

Boundless Bio

www.boundlessbio.com

 
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.boundlessbio.com
  • 11099 North Torrey Pines Road Suite 280
    La Jolla, CA USA 92037
  • Phone: 858.766.9912

Executives

Name Title Contact Details
Rebecca Jones
 Associate General Counsel Profile
Jessica Oien
 General Counsel and Corporate Secretary Profile

Similar Companies

Allied Safety Associates

Allied Safety Associates is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Akriveia Therapeutics

`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comfort Safety Products

Comfort Safety Products is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Century Therapeutics

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.